CD70 and acute myeloid leukemia: To prevent the severe side effect induced by the CAR T-cell treatment, several approaches were utilized including limiting the persistence of CAR T cells through engineering a “safety switch” (Di Stasi et al., 2011); novel developed CAR T cells targeting CLL-1 or CD70 are efficient against AML without being toxic to normal HSCs (Tashiro et al., 2017; Wang et al., 2018; Sauer et al., 2021).